Type I insulin-like growth factor receptor as a therapeutic target in cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16287993.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Data from experimental model systems and population studies have implicated type I insulin-like growth factor receptor (IGF1R) signaling in many different human cancers. Drugs to disrupt IGF1R function have been developed and are now entering clinical trial. This brief review will identify key areas to consider as these clinical trials move forward.
Medical subject headings
- Neoplasms
- Receptor, IGF Type 1